Sensei Biotherapeutics (SNSE)
NASDAQ:SNSE
Top Page
Sensei Biotherapeutics
(NASDAQ:SNSE)
Select Model
Select Model
Rating:51Neutral
Price Target:
$9.00
▼(-21.19% Downside)
Action:ReiteratedDate:01/23/26
The score is held down primarily by weak fundamentals—minimal/negative revenue, persistent losses, and ongoing cash burn with a shrinking equity base—implying continued financing risk. Technicals are a relative bright spot with price trading above key moving averages and positive MACD, but valuation remains constrained by negative earnings, and corporate events add uncertainty due to program discontinuation and strategic review.
Positive Factors
Low leverage / conservative debt profile
Sensei's very low debt-to-equity (~0.09) reduces interest burden and financial distress risk, giving management more flexibility to finance R&D through equity or partnerships. This conservatism supports runway extension and strategic options over the next several months.
Negative Factors
Sustained cash burn and weak cash generation
Persistent negative OCF/FCF (~-$22.4M TTM) shows operations consume cash rather than generate it. This structural cash burn necessitates external financing or dilutive capital raises, which can erode shareholder value and constrain long-term program funding and development timelines.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / conservative debt profile
Sensei's very low debt-to-equity (~0.09) reduces interest burden and financial distress risk, giving management more flexibility to finance R&D through equity or partnerships. This conservatism supports runway extension and strategic options over the next several months.
Read all positive factors
Sensei Biotherapeutics (SNSE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.80M
Dividend YieldN/A
Average Volume (3M)38.93K
Price to Earnings (P/E)―
Beta (1Y)1.77
Revenue GrowthN/A
EPS Growth9.63%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.62
Shares Outstanding1,261,290
10 Day Avg. Volume109,584
30 Day Avg. Volume38,927
Financial Highlights & Ratios
PEG Ratio4.98
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-9.92
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue-6.03
Enterprise Value/Gross Profit-142.10
Enterprise Value/Ebitda-1.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-15.05
Revenue Forecast (FY)N/A
Sensei Biotherapeutics Business Overview & Revenue Model
Company Description
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is ...
How the Company Makes Money
Sensei Biotherapeutics makes money primarily through the development and potential commercialization of its proprietary immunotherapy products. The company's revenue model is centered around advancing its product candidates through clinical trials...
Sensei Biotherapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -4.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -206.00K | -551.00K | -571.00K | -1.81M | -685.00K | -209.00K |
| EBITDA | -23.85M | -29.52M | -33.39M | -46.56M | -35.44M | -18.20M |
| Net Income | -24.14M | -30.16M | -34.10M | -48.59M | -36.79M | -20.10M |
Balance Sheet | ||||||
| Total Assets | 27.59M | 45.36M | 74.37M | 118.38M | 153.22M | 21.43M |
| Cash, Cash Equivalents and Short-Term Investments | 25.04M | 41.34M | 65.76M | 107.12M | 147.62M | 16.60M |
| Total Debt | 2.02M | 3.85M | 6.21M | 8.03M | 2.35M | 685.00K |
| Total Liabilities | 4.58M | 6.97M | 9.48M | 14.97M | 6.71M | 5.54M |
| Stockholders Equity | 23.01M | 38.39M | 64.89M | 103.41M | 146.51M | 15.89M |
Cash Flow | ||||||
| Free Cash Flow | -22.40M | -24.82M | -32.20M | -39.35M | -32.28M | -18.91M |
| Operating Cash Flow | -22.38M | -24.67M | -32.02M | -39.03M | -30.26M | -17.70M |
| Investing Cash Flow | 14.54M | 22.44M | 38.41M | 49.95M | -143.12M | -1.40M |
| Financing Cash Flow | -728.00K | -787.00K | -11.17M | -287.00K | 163.94M | 35.45M |
Sensei Biotherapeutics Technical Analysis
Positive
11.42
Price Trends
19.91
Positive
14.51
Positive
11.62
Positive
Market Momentum
3.14
Positive
68.10
Neutral
58.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNSE, the sentiment is Positive. The current price of 11.42 is below the 20-day moving average (MA) of 30.92, below the 50-day MA of 19.91, and below the 200-day MA of 11.62, indicating a bullish trend. The MACD of 3.14 indicates Positive momentum. The RSI at 68.10 is Neutral, neither overbought nor oversold. The STOCH value of 58.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNSE.
Sensei Biotherapeutics Risk Analysis
Sensei Biotherapeutics disclosed 67 risk factors in its most recent earnings report. Sensei Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sensei Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $37.80M | -0.65 | -80.00% | ― | ― | 9.63% | |
45 Neutral | $14.89M | -1.68 | -94.94% | ― | ― | 49.10% | |
44 Neutral | $7.06M | -1.09 | -207.73% | ― | 1.70% | -111.67% | |
43 Neutral | $13.23M | -0.59 | -248.91% | ― | ― | 79.31% | |
41 Neutral | $8.24M | -0.31 | -97.58% | ― | -46.88% | 34.83% |
* Healthcare Sector Average
SNSE
Sensei Biotherapeutics
29.97
20.90
230.50%
CLRB
Cellectar Biosciences
3.01
-8.57
-74.01%
COCP
Cocrystal Pharma
1.06
-0.42
-28.38%
BRTX
BioRestorative Therapies
0.29
-1.63
-84.74%
BOLT
Bolt Biotherapeutics
4.29
-4.11
-48.93%
Sensei Biotherapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Sensei Biotherapeutics Updates Executive Retention and Compensation Agreements
Positive
Dec 23, 2025
On December 22, 2025, Sensei Biotherapeutics, Inc. entered into amended retention agreements with President and Principal Executive Officer Christopher Gerry and Senior Vice President of Finance and Principal Finance and Accounting Officer Josiah ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.